150 related articles for article (PubMed ID: 25015634)
1. Development and validation of a tetra-primer amplification refractory mutation system-polymerase chain reaction combined with melting analysis-assay for clinical JAK2 V617F mutation detection.
Liu W; Hu T; Chen Y; Zhang X; Gu X; Guan M
Mol Diagn Ther; 2014 Oct; 18(5):579-85. PubMed ID: 25015634
[TBL] [Abstract][Full Text] [Related]
2. Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.
Ochsenreither S; Reinwald M; Thiel E; Burmeister T
Mol Diagn Ther; 2010 Jun; 14(3):185-90. PubMed ID: 20560681
[TBL] [Abstract][Full Text] [Related]
3. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system.
Olsen RJ; Tang Z; Farkas DH; Bernard DW; Zu Y; Chang CC
Arch Pathol Lab Med; 2006 Jul; 130(7):997-1003. PubMed ID: 16831057
[TBL] [Abstract][Full Text] [Related]
4. A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.
Wu Z; Zhang Y; Zhang X; Xu X; Kang Z; Li S; Zhang C; Su B; Guan M
Biomed Res Int; 2014; 2014():458457. PubMed ID: 24729973
[TBL] [Abstract][Full Text] [Related]
5. Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.
Lin CY; Ho CM; Tamamyan G; Yang SF; Peng CT; Chang JG
J Clin Lab Anal; 2016 Nov; 30(6):838-844. PubMed ID: 27169616
[TBL] [Abstract][Full Text] [Related]
6. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
7. A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation.
Koksal V; Etlik O; Arican-Baris ST; Baris I
Genet Test; 2007; 11(4):463-6. PubMed ID: 18294066
[TBL] [Abstract][Full Text] [Related]
8. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.
Wu Z; Yuan H; Zhang X; Liu W; Xu J; Zhang W; Guan M
PLoS One; 2011; 6(10):e26534. PubMed ID: 22028900
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
[TBL] [Abstract][Full Text] [Related]
10. Optimization of a Low-Cost, Sensitive PNA Clamping PCR Method for JAK2 V617F Variant Detection.
Di Francia R; Crisci S; Muto T; Giancola C; Petriccone L; Catapano O; Cummarro A; Pinto A; Frigeri F
J Appl Lab Med; 2020 Jul; 5(4):643-655. PubMed ID: 32407536
[TBL] [Abstract][Full Text] [Related]
11. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
12. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
[TBL] [Abstract][Full Text] [Related]
13. Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
Reading NS; Lim MS; Elenitoba-Johnson KS
Mol Diagn Ther; 2006; 10(5):311-7. PubMed ID: 17022694
[TBL] [Abstract][Full Text] [Related]
14. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
Chen Q; Lu P; Jones AV; Cross NC; Silver RT; Wang YL
J Mol Diagn; 2007 Apr; 9(2):272-6. PubMed ID: 17384221
[TBL] [Abstract][Full Text] [Related]
15. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis.
Murugesan G; Aboudola S; Szpurka H; Verbic MA; Maciejewski JP; Tubbs RR; Hsi ED
Am J Clin Pathol; 2006 Apr; 125(4):625-33. PubMed ID: 16627272
[TBL] [Abstract][Full Text] [Related]
16. Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis.
Cao HC; Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF
J Clin Lab Anal; 2011; 25(4):300-4. PubMed ID: 21786333
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
18. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
Tan AY; Westerman DA; Dobrovic A
Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
[TBL] [Abstract][Full Text] [Related]
19. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform.
Qian J; Lin J; Yao DM; Chen Q; Xiao GF; Ji RB; Li Y; Yang J; Qian Z
Clin Chim Acta; 2010 Dec; 411(23-24):2097-100. PubMed ID: 20728437
[TBL] [Abstract][Full Text] [Related]
20. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
